**AI-Enhanced Personalized Oncology Trials**

**Transforming Cancer Research Through Intelligent Precision Medicine**

**Vidya HK**

**St Philomen’s college Mysuru**

**Abstract**

The landscape of oncology research is rapidly evolving with the advent of artificial intelligence (AI), particularly in the design and execution of personalized clinical trials. Traditional oncology trials often suffer from limitations such as rigid protocols, inefficient patient recruitment, and population heterogeneity, which hinder the evaluation of targeted therapies. AI presents a transformative opportunity to overcome these challenges by enabling data-driven, adaptive, and personalized trial methodologies. This paper explores the integration of AI technologies across key areas of oncology trials, including patient stratification, adaptive trial designs, and predictive analytics for treatment response and toxicity. Machine learning algorithms can analyze genomic data, electronic health records, and other multidimensional datasets to identify suitable candidates for trials, enhancing both the efficiency and precision of patient recruitment. AI also supports real-time trial modifications, making adaptive designs more flexible and responsive to emerging data. Additionally, predictive models aid in forecasting treatment efficacy and potential adverse effects, contributing to safer and more effective therapeutic development. While challenges such as data standardization, regulatory acceptance, and algorithm transparency remain, the ongoing advancements in AI capabilities and collaborative frameworks offer a promising future for AI-driven personalized oncology trials. This paper underscores the potential of AI to revolutionize cancer research by aligning trial methodologies with the principles of precision medicine.

**Introduction**

Oncology has undergone a paradigm shift in recent years, transitioning from a generalized treatment framework to more personalized approaches. Personalized oncology aims to tailor treatments based on the unique genetic, molecular, and clinical characteristics of individual patients [1]. Despite these advancements, conventional clinical trials often fall short in evaluating treatments for such heterogeneous populations due to rigid protocols, broad inclusion criteria, and limited adaptability [2]. As a result, traditional trial designs can obscure the efficacy of potentially life-saving treatments in specific patient subgroups. Artificial Intelligence (AI) offers transformative potential to address these shortcomings and usher in a new era of personalized oncology trials [3].

AI systems, particularly those powered by machine learning and deep learning algorithms, are capable of analyzing vast and complex datasets—including genomic profiles, histopathological images, electronic health records (EHRs), and real-time patient monitoring data [3-5]. These capabilities allow AI to uncover intricate patterns and predict therapeutic responses at a level previously unattainable. By stratifying patients more effectively and matching them to the most promising interventions, AI enhances trial design, accelerates patient recruitment, and optimizes outcome assessment [4].

Furthermore, adaptive trial designs can be significantly improved through AI, enabling real-time modifications based on incoming data. For instance, AI can dynamically adjust cohort sizes, inclusion criteria, or even intervention arms to reflect emerging efficacy signals [5]. This not only reduces the duration and cost of trials but also increases their ethical viability by minimizing exposure to ineffective treatments. Additionally, AI aids in identifying biomarkers and surrogate endpoints that can serve as early indicators of treatment success, offering regulators and sponsors faster pathways to approval [6].

As we continue to witness an explosion in cancer-related data from multiple sources—ranging from next-generation sequencing to wearable devices—there is a growing need for intelligent systems that can integrate, interpret, and act upon this information in clinically meaningful ways [7]. AI meets this need by enabling continuous learning and decision-making across all phases of oncology trials [8].

AI-enhanced personalized oncology trials represent the convergence of precision medicine and computational innovation. By leveraging AI to design, conduct, and analyze clinical trials, researchers and clinicians can ensure that the right patients receive the right treatments at the right time. This evolution holds promise for not only improving patient outcomes but also reshaping the future landscape of cancer research.

**AI-Driven Patient Stratification and Recruitment**

One of the most critical aspects of a successful oncology trial is the accurate stratification and recruitment of participants. Traditional recruitment methods often rely on basic clinical or demographic characteristics, resulting in heterogeneous trial populations that may not respond uniformly to a treatment [9]. AI offers a solution through its ability to analyze multidimensional datasets, including genomic profiles, tumor phenotypes, EHRs, and lifestyle factors, to identify patients who are most likely to benefit from a particular therapy [9-11].

Machine learning algorithms can process these datasets to discover biomarkers or patient subgroups with specific molecular signatures. This allows for stratification based on underlying disease mechanisms rather than superficial traits [10]. For instance, patients with similar KRAS mutations or PD-L1 expression levels can be grouped together, enabling more precise assessment of drug efficacy. Moreover, AI can incorporate longitudinal data to account for disease progression and treatment response over time, further refining stratification [11].

In addition to stratification, AI enhances recruitment efficiency by automatically scanning patient databases and registries to identify eligible participants [12]. Natural language processing (NLP) can extract relevant information from unstructured clinical notes to match patients with trials based on nuanced eligibility criteria. This accelerates the recruitment process and ensures a better fit between patient characteristics and trial requirements [13].

AI also facilitates the inclusion of underrepresented populations by identifying disparities in access and suggesting ways to target recruitment efforts accordingly. This is crucial for improving trial diversity and generalizability of results [14]. By using AI for patient stratification and recruitment, clinical trials become more targeted, efficient, and equitable, ultimately leading to faster discoveries and better patient outcomes [15].

**Adaptive Trial Designs with AI Integration**

Adaptive clinical trial designs offer a flexible and data-driven approach to testing therapeutic interventions, and when integrated with AI, their potential is significantly amplified. Traditional fixed trial designs are often limited in scope and inefficient in responding to emerging data [16]. Adaptive trials, on the other hand, allow for real-time adjustments to various parameters—such as dosage, sample size, or patient cohort allocation—based on interim results. AI enhances this adaptability by providing continuous analysis of incoming data, enabling faster and more informed decisions during the course of a trial [17].

Machine learning models can be trained on historical and real-time trial data to predict outcomes, simulate scenarios, and recommend modifications to trial protocols [18-20]. For example, AI can help identify early signs of drug efficacy or toxicity, prompting mid-trial changes such as expanding promising treatment arms or discontinuing ineffective ones. This dynamic approach reduces resource wastage and enhances the ethical framework of the trial by minimizing patient exposure to suboptimal therapies [19].

Moreover, reinforcement learning algorithms can optimize trial pathways by learning which actions—such as adjusting dosage or altering randomization ratios—lead to improved outcomes [20]. These decisions are data-informed and can be personalized based on the evolving characteristics of the participant population [21].

AI also assists in the development of surrogate endpoints and composite biomarkers that serve as early indicators of long-term outcomes. This can expedite trial timelines and improve the likelihood of regulatory approval. In decentralized or hybrid trial models, AI supports real-time data capture and remote monitoring, allowing adjustments to be made without disrupting the trial’s flow [22].

By incorporating AI into adaptive trial design, oncology research becomes more efficient, responsive, and patient-centered. This synergy ultimately accelerates the development of life-saving cancer therapies while maintaining scientific rigor and operational efficiency [23].

**Predictive Analytics for Treatment Response and Toxicity**

Predicting treatment response and potential toxicity is a major challenge in oncology trials, especially given the variability in patient genetics, tumor biology, and environmental influences [24]. Artificial intelligence brings a powerful solution through predictive analytics, which can identify patterns in complex datasets to forecast individual outcomes. These predictions can inform both trial design and clinical decision-making, significantly enhancing the safety and efficacy of investigational therapies [25].

Machine learning algorithms can be trained on retrospective clinical trial data, real-world evidence, and omics data to predict which patients are most likely to respond positively to specific treatments. For example, in immunotherapy trials, AI can analyze tumor-infiltrating lymphocyte levels, mutational burden, and PD-L1 expression to forecast response likelihood. These insights help enrich trials with responders and reduce variability in outcomes [26].

AI also plays a crucial role in toxicity prediction. By integrating clinical lab values, pharmacogenomics, prior treatment history, and comorbidities, machine learning models can anticipate adverse events before they occur [25-27]. This is especially important in oncology, where treatments such as chemotherapy and targeted therapies can cause severe side effects. Early identification of at-risk patients enables dose adjustments, supportive care planning, or selection of alternative therapies, thereby improving patient safety and trial integrity [27].

Furthermore, deep learning models can process medical imaging and pathology data to assess tumor heterogeneity, a key determinant of both response and toxicity. As AI continues to evolve, these models will become increasingly adept at interpreting multimodal data to deliver real-time, actionable insights [25].

Predictive analytics powered by AI thus transforms oncology trials from static evaluations to dynamic, personalized assessments. This approach not only reduces trial failure rates but also enhances patient outcomes by ensuring that the right treatment is administered to the right patient at the right time [26-27].

**Personalized Outcome Monitoring and Continuous Learning**

Artificial Intelligence is not just reshaping the design and analysis of oncology trials, but also enabling continuous learning throughout the treatment lifecycle. In traditional frameworks, clinical trials often produce a fixed dataset that becomes obsolete as new treatments, biomarkers, and patient populations emerge. AI-powered continuous learning models, however, allow for ongoing refinement of therapeutic strategies even after a trial concludes. By leveraging real-time patient data from electronic health records, wearable devices, and mobile applications, these systems can adapt to evolving clinical evidence, ensuring that future interventions are based on the most current understanding of disease dynamics [28–29].

Moreover, AI facilitates personalized outcome monitoring by integrating longitudinal data streams. Machine learning models can track patient responses over time, identifying subtle shifts in biomarkers or clinical metrics that may signal the need for treatment adjustments. For example, patients whose initial therapy shows diminishing returns might be flagged early for alternative regimens, preventing disease progression and improving long-term survival rates [30]. Additionally, deep reinforcement learning approaches enable adaptive decision-making, where the system continuously learns from patient outcomes to refine its predictive algorithms. This ensures that oncology trials evolve in tandem with clinical practice, making them more relevant and impactful [31–32].

**Addressing Ethical and Regulatory Challenges**

While the integration of AI into oncology trials holds great promise, it also raises significant ethical and regulatory considerations. Transparency and explainability of AI models remain critical concerns. Regulators and clinicians alike need to understand the rationale behind AI-driven recommendations. Efforts to develop interpretable AI frameworks, such as those employing attention mechanisms or feature importance scores, help address this challenge by offering insights into the key variables influencing model predictions [33–34]. Ensuring that these models are transparent and understandable is essential for regulatory approval and clinician acceptance.

Another pressing issue is data privacy and security. Oncology trials generate vast amounts of sensitive patient data, including genetic information, imaging scans, and treatment outcomes. Adhering to stringent data protection frameworks like GDPR or HIPAA is vital to maintain patient trust. Moreover, federated learning approaches are gaining traction, enabling AI models to be trained on decentralized datasets without the need to transfer sensitive patient information, thereby enhancing privacy and compliance with regulatory standards [35–36].

Ethical challenges also extend to the potential for algorithmic bias. If training datasets are not representative of the diverse populations affected by cancer, AI models may produce skewed results that disadvantage certain demographic groups. To address this, ongoing efforts focus on curating diverse, inclusive datasets and implementing fairness constraints within the algorithms themselves [37–38]. Such measures help ensure that AI-driven oncology trials are equitable, trustworthy, and aligned with ethical principles.

**The Future of AI in Oncology Trials**

The ongoing development of AI technologies, coupled with the expanding availability of multi-modal cancer data, suggests a future where oncology trials are not only more efficient but also more inclusive and effective. Advances in natural language processing are enabling the integration of unstructured clinical notes, pathology reports, and literature into trial datasets, further enhancing the scope of data-driven insights [39–40]. Meanwhile, multi-omics integration—combining genomics, proteomics, and metabolomics—holds the potential to uncover new biomarkers and therapeutic targets that were previously undetectable [41–42].

In addition, the growing adoption of decentralized and hybrid trial models, supported by AI-based telemedicine and remote monitoring solutions, promises to make clinical research more accessible to patients worldwide. These approaches reduce barriers to participation, increase trial diversity, and generate more generalizable results [43–44]. Machine learning models trained on data from these decentralized trials can also better capture real-world treatment patterns and outcomes, further bridging the gap between clinical research and everyday practice [45–46].

As AI continues to evolve, its integration into oncology trials will likely expand to include more sophisticated reinforcement learning strategies, augmented reality tools for clinician support, and even AI-driven trial protocols that adapt autonomously based on real-time outcomes. The ultimate goal is a seamless and continuous cycle of learning, where every patient interaction contributes to a deeper understanding of cancer biology and more effective therapies. This vision aligns closely with the broader goals of precision medicine, ensuring that cancer treatment is tailored, timely, and transformative [47–51].

In summary, AI-driven oncology trials represent a paradigm shift in how cancer treatments are developed, tested, and refined. By leveraging the power of AI to stratify patients, adapt trial designs, predict outcomes, and address ethical challenges, researchers are paving the way for a more efficient, equitable, and personalized approach to cancer care.

**Conclusion**

AI-enhanced personalized oncology trials represent a fundamental advancement in the evolution of cancer research and treatment development. By integrating machine learning, deep learning, and predictive analytics into every stage of the clinical trial process—from patient stratification to outcome assessment—these approaches significantly enhance precision, efficiency, and patient safety. Traditional clinical trials are often limited by rigid designs and population heterogeneity, but AI enables real-time adjustments and personalized decision-making that align better with the complexities of cancer biology.

The use of AI in stratifying patients ensures that trial populations are more homogeneous in terms of molecular profiles and disease behavior, leading to clearer efficacy signals and faster conclusions. Adaptive trial designs powered by AI offer an ethical and economical advantage by allowing mid-trial modifications based on interim data, thus minimizing exposure to ineffective therapies and accelerating drug development timelines. Moreover, predictive models for treatment response and toxicity improve patient care by tailoring interventions to individual risk profiles.

Despite the enormous potential, challenges remain in implementing AI in clinical trials. These include data standardization, model interpretability, regulatory approval, and integration into existing clinical workflows. Ensuring transparency and addressing algorithmic bias are also essential for maintaining trust among stakeholders, including clinicians, regulators, and patients.

Nonetheless, as data ecosystems become more robust and AI algorithms continue to evolve, the barriers to adoption are expected to diminish. Collaborative efforts between oncologists, data scientists, regulatory bodies, and technology developers will be key to unlocking the full potential of AI in oncology trials.

In conclusion, AI-enhanced personalized oncology trials are poised to revolutionize cancer research. By enabling more intelligent, adaptive, and patient-centric approaches to clinical investigation, AI has the potential to not only accelerate the development of effective cancer therapies but also ensure that every patient receives treatment tailored to their unique biological profile.

**References**

1. Amaral, R., Zimmermann, M., Ma, A.-H., Zhang, H., Swiech, K., & Pan, C. (2020). A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models. Cancers, 12(5), 1304. https://doi.org/10.3390/cancers12051304
2. Askin, S., Burkhalter, D., Calado, G., & Dakrouni, S. E. (2023). Artificial Intelligence Applied to clinical trials: opportunities and challenges [Review of Artificial Intelligence Applied to clinical trials: opportunities and challenges]. Health and Technology, 13(2), 203. Springer Science+Business Media. https://doi.org/10.1007/s12553-023-00738-2
3. Bongurala, A. R., Save, D., & Virmani, A. (2025). Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1533910
4. Chow, R., Midroni, J., Kaur, J., Boldt, G., Liu, G., Eng, L., Liu, F., Haibe‐Kains, B., Lock, M., & Raman, S. (2023). Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis [Review of Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis]. JNCI Journal of the National Cancer Institute, 115(4), 365. Oxford University Press. https://doi.org/10.1093/jnci/djad013
5. Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J. H., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., Zhang, C., Lunceford, J., Joe, A. K., Cheng, J. D., Webber, A. L., Ibrahim, N., Plimack, E. R., Ott, P. A., Seiwert, T. Y., … Kaufman, D. R. (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science, 362(6411). https://doi.org/10.1126/science.aar3593
6. Deliu, N., Williams, J. J., & Chakraborty, B. (2024). Reinforcement Learning in Modern Biostatistics: Constructing Optimal Adaptive Interventions. International Statistical Review. https://doi.org/10.1111/insr.12583
7. Dixon, D., Sattar, H., Moros, N., Kesireddy, S. R., Ahsan, H., Lakkimsetti, M., Fatima, M., Doshi, D., Sadhu, K., & Hassan, M. J. (2024). Unveiling the Influence of AI Predictive Analytics on Patient Outcomes: A Comprehensive Narrative Review. Cureus. https://doi.org/10.7759/cureus.59954
8. Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024). New clinical trial design in precision medicine: discovery, development and direction [Review of New clinical trial design in precision medicine: discovery, development and direction]. Signal Transduction and Targeted Therapy, 9(1). Springer Nature. https://doi.org/10.1038/s41392-024-01760-0
9. Gaton-Johansson, F., Watkins, C. C., Kanu, I. K. amara, Whitehouse, E., Sarenmalm, E. K., Brovall, M., & Kozachik, S. (2015). The Effects of Symptoms on Quality of Life during Chemotherapy in African-American Women with Breast Cancer. PubMed, 26(2), 7. https://pubmed.ncbi.nlm.nih.gov/27045153
10. Glaab, E., Rauschenberger, A., Banzi, R., Gerardi, C., Garcia, P., & Demotes‐Mainard, J. (2021). Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review [Review of Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review]. BMJ Open, 11(12). BMJ. https://doi.org/10.1136/bmjopen-2021-053674
11. Hamer, D. M. den, Schoor, P., Polak, T. B., & Kapitan, D. (2023). Improving Patient Pre-screening for Clinical Trials: Assisting Physicians with Large Language Models. arXiv (Cornell University). https://doi.org/10.48550/arXiv.2304.
12. Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial Intelligence for Clinical Trial Design [Review of Artificial Intelligence for Clinical Trial Design]. Trends in Pharmacological Sciences, 40(8), 577. Elsevier BV. https://doi.org/10.1016/j.tips.2019.05.005
13. Huang, S., Chaudhary, K., & Garmire, L. X. (2017). More Is Better: Recent Progress in Multi-Omics Data Integration Methods [Review of More Is Better: Recent Progress in Multi-Omics Data Integration Methods]. Frontiers in Genetics, 8. Frontiers Media. https://doi.org/10.3389/fgene.2017.00084
14. Ledford, H. (2018). How Facebook and Twitter could be the next disruptive force in clinical trials. Nature, 563(7731), 312. https://doi.org/10.1038/d41586-018-07351-8
15. Li, Y.-H., Li, Y., Wei, M.-Y., & Li, G. (2024). Innovation and challenges of artificial intelligence technology in personalized healthcare [Review of Innovation and challenges of artificial intelligence technology in personalized healthcare]. Scientific Reports, 14(1). Nature Portfolio. https://doi.org/10.1038/s41598-024-70073-7
16. Messiou, C., Lee, R., & Salto‐Tellez, M. (2023). Multimodal analysis and the oncology patient: Creating a hospital system for integrated diagnostics and discovery. Computational and Structural Biotechnology Journal, 21, 4536. https://doi.org/10.1016/j.csbj.2023.09.014
17. Mourya, A., Jobanputra, B., & Pai, R. (2024). AI-powered clinical trials and the imperative for regulatory transparency and accountability. Health and Technology. https://doi.org/10.1007/s12553-024-00904-0
18. Papachristou, N., Kotronoulas, G., Δικαίος, Ν., Allison, S. J., Eleftherochorinou, H., Rai, T., Kunz, H. R., Barnaghi, P., Miaskowski, C., & Bamidis, P. D. (2023). Digital Transformation of Cancer Care in the Era of Big Data, Artificial Intelligence and Data-Driven Interventions: Navigating the Field. Seminars in Oncology Nursing, 39(3), 151433. https://doi.org/10.1016/j.soncn.2023.151433
19. Saltonstall, P. L., Ross, H., & KIM, P. T. (2023). The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success. Milbank Quarterly, 102(1), 83. https://doi.org/10.1111/1468-0009.12680
20. Shimizu, H., & Nakayama, K. I. (2020). Artificial intelligence in oncology [Review of Artificial intelligence in oncology]. Cancer Science, 111(5), 1452. Wiley. https://doi.org/10.1111/cas.14377
21. Thaker, N. G., Dicker, A. P., Loaiza‐Bonilla, A., Wallace, A. F., Kolman, D., Ruggles, A. G., Manda, S., Frank, S. J., Orio, P. F., & Doria, C. (2024). The Role of Artificial Intelligence in Early Cancer Detection: Exploring Early Clinical Applications. AI in Precision Oncology, 1(2), 91. https://doi.org/10.1089/aipo.2023.0011
22. Thakur, G. K., Thakur, A., Kulkarni, S., Khan, N., & Khan, S. (2024). Deep Learning Approaches for Medical Image Analysis and Diagnosis. Cureus. https://doi.org/10.7759/cureus.59507
23. Thorlund, K., Häggström, J., Park, J., & Mills, E. J. (2018). Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. https://doi.org/10.1136/bmj.k698
24. Varatharajah, Y., & Berry, B. (2022). A Contextual-Bandit-Based Approach for Informed Decision-Making in Clinical Trials. Life, 12(8), 1277. https://doi.org/10.3390/life12081277
25. Wojtara, M., Rana, E., Rahman, T., Khanna, P., & Singh, H. (2023). Artificial intelligence in rare disease diagnosis and treatment [Review of Artificial intelligence in rare disease diagnosis and treatment]. Clinical and Translational Science, 16(11), 2106. Wiley. https://doi.org/10.1111/cts.13619
26. Zeng, J., & Shufean, M. A. (2021). Molecular-based precision oncology clinical decision making augmented by artificial intelligence [Review of Molecular-based precision oncology clinical decision making augmented by artificial intelligence]. Emerging Topics in Life Sciences, 5(6), 757. Portland Press. https://doi.org/10.1042/etls20210220
27. Zou, J., & Schiebinger, L. (2021). Ensuring that biomedical AI benefits diverse populations [Review of Ensuring that biomedical AI benefits diverse populations]. EBioMedicine, 67, 103358. Elsevier BV. <https://doi.org/10.1016/j.ebiom.2021.103358>
28. Davuluri, M. (2020). AI-Driven Drug Discovery: Accelerating the Path to New Treatments. International Journal of Machine Learning and Artificial Intelligence, 1(1).
29. Yarlagadda, V. S. T. (2019). AI for Remote Patient Monitoring: Improving Chronic Disease Management and Preventive Care. International Transactions in Artificial Intelligence, 3(3).
30. Deekshith, A. (2019). From Clinics to Care: A Technological Odyssey in Healthcare and Medical Manufacturing. Transactions on Latest Trends in IoT, 2(2).
31. Kolla, V. R. K. (2021). Cyber security operations centre ML framework for the needs of the users. International Journal of Machine Learning for Sustainable Development, 3(3), 11-20.
32. Alladi, D. (2023). AI in Genomics: Unlocking the Future of Precision Medicine. International Numeric Journal of Machine Learning and Robots, 7(7).
33. Davuluri, M. (2017). Bridging the Healthcare Gap in Smart Cities: The Role of IoT Technologies in Digital Inclusion. International Transactions in Artificial Intelligence, 1(1).
34. Yarlagadda, V. S. T. (2024). Machine Learning for Predicting Mental Health Disorders: A Data-Driven Approach to Early Intervention. International Journal of Sustainable Development in Computing Science, 6(4).
35. Kolla, V. R. K. (2020). India’s Experience with ICT in the Health Sector. Transactions on Latest Trends in Health Sector, 12, 12.
36. Deekshith, A. (2023). Scalable Machine Learning: Techniques for Managing Data Volume and Velocity in AI Applications. International Scientific Journal for Research, 5(5).
37. Davuluri, M. (2021). AI for Chronic Disease Management: Improving Long-Term Patient Outcomes. International Journal of Machine Learning and Artificial Intelligence, 2(2).
38. Yarlagadda, V. S. T. (2018). AI-Powered Virtual Health Assistants: Transforming Patient Care and Healthcare Delivery. International Journal of Sustainable Development in Computer Science Engineering, 4(4).
39. Kolla, V. (2022). Machine Learning Application to automate and forecast human behaviours. International Journal of Machine Learning for Sustainable Development, 4(1), 1-10.
40. Davuluri, M. (2024). AI in Healthcare Fraud Detection: Ensuring Integrity in Medical Billing. International Machine learning journal and Computer Engineering, 7(7).
41. Yarlagadda, V. (2017). AI in Precision Oncology: Enhancing Cancer Treatment Through Predictive Modeling and Data Integration. Transactions on Latest Trends in Health Sector, 9(9).
42. Deekshith, A. (2022). AI-Driven Early Warning Systems for Natural Disaster Prediction. International Journal of Sustainable Development in Computing Science, 4(4).
43. Kolla, V. R. K. (2021). Prediction in Stock Market using AI. Transactions on Latest Trends in Health Sector, 13, 13.
44. Alladi, D. (2021). Revolutionizing Emergency Care with AI: Predictive Models for Critical Interventions. International Numeric Journal of Machine Learning and Robots, 5(5).
45. Davuluri, M. (2021). AI in Personalized Oncology: Revolutionizing Cancer Care. International Machine learning journal and Computer Engineering, 4(4).
46. Yarlagadda, V. S. T. (2019). AI-Enhanced Drug Discovery: Accelerating the Development of Targeted Therapies. International Scientific Journal for Research, 1 (1).
47. Kolla, V. R. K. (2016). Forecasting Laptop Prices: A Comparative Study of Machine Learning Algorithms for Predictive Modeling. International Journal of Information Technology & Management Information System.
48. Deekshith, A. (2018). Seeding the Future: Exploring Innovation and Absorptive Capacity in Healthcare 4.0 and HealthTech. Transactions on Latest Trends in IoT, 1(1), 90-99.
49. Alladi, D. (2019). AI in Rehabilitation Medicine: Personalized Therapy for Improved Recovery. International Machine learning journal and Computer Engineering, 2(2).
50. Kolla, V. R. K. (2020). Forecasting the Future: A Deep Learning Approach for Accurate Weather Prediction. International Journal in IT & Engineering (IJITE), 2018, Available at SSRN: https://ssrn.com/abstract=4413727.
51. Davuluri, M. (2022). Comparative Study of Machine Learning Algorithms in Predicting Diabetes Onset Using Electronic Health Records. Research-gate journal, 8(8).